|Bid||399.98 x 1100|
|Ask||547.05 x 800|
|Day's range||542.32 - 556.32|
|52-week range||462.61 - 832.70|
|Beta (5Y monthly)||0.93|
|PE ratio (TTM)||2.49|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, TMO and BIO will likely fare this time.